Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909361 | 0.94 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL4911810 | 0.91 | GABRA2 (0.58) | CNR1CNR2 | |
| SCHEMBL4902889 | 0.89 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL3081610 | 0.89 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL908827 | 0.86 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL4914114 | 0.85 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL4907403 | 0.85 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL908614 | 0.85 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL3089742 | 0.84 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4632916 | 0.84 | CNR1 (0.59) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR1 597/4885CNR2 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.